| domain | syndrome-specific finding | ontology/identifier suggestion | evidence strength or caveat |
|---|---|---|---|
| Disease identity | PPM-X syndrome corresponds to **X-linked intellectual disability-psychosis-macroorchidism syndrome** | **MONDO:0010235**; disease label: X-linked intellectual disability–psychosis–macroorchidism syndrome | Strong disease-entity resolution from Open Targets disease mapping; rare-disease nomenclature remains variable across MECP2 literature (pqac-00000000) |
| Causal gene | Disease is an **MECP2-related disorder** | **MECP2**; Ensembl **ENSG00000169057** | Strong gene–disease association in curated target–disease resources and historical literature linkage (pqac-00000000) |
| Key pathogenic variant | Classic PPM-X is centered on recurrent **MECP2 p.Ala140Val (A140V)** missense variation | HGVS protein: **p.Ala140Val** | Strong historical syndrome association, but ultra-small number of pedigrees; variant-specific evidence is much narrower than for common RTT variants (pqac-00000000, pqac-00000009) |
| Etiology / variant class | Germline **missense** variant affecting MeCP2 function | Sequence Ontology suggestion: **missense_variant** | Syndrome-specific primary reports exist, but most mechanistic detail comes from broader MeCP2 functional literature rather than direct PPM-X experiments (pqac-00000000, pqac-00000005, pqac-00000009) |
| Inheritance | **X-linked** inheritance with marked sex effects; males predominantly affected, females may be asymptomatic or milder depending in part on X-inactivation | HPO inheritance term suggestion: **X-linked inheritance** | Strong from syndrome name and broader MECP2 male/female literature; exact penetrance for PPM-X specifically is not well quantified (pqac-00000001, pqac-00000008) |
| Core phenotype: neurodevelopment | **Intellectual disability / developmental impairment** is a core syndrome component | HPO suggestion: **Intellectual disability (HP:0001249)** | Strong syndrome-defining feature; exact severity distribution for PPM-X is not robustly quantified in modern cohorts (pqac-00000000, pqac-00000002) |
| Core phenotype: psychiatric | **Psychosis and/or bipolar/manic-depressive illness** are hallmark PPM-X features distinguishing it from many other MECP2 disorders | HPO suggestions: **Psychosis (HP:0000709)**; **Bipolar affective disorder** | Strong syndrome-specific historical description, but based on very few reported families/patients (pqac-00000000, pqac-00000001) |
| Core phenotype: corticospinal | **Pyramidal signs / spasticity** reported in affected males | HPO suggestions: **Spasticity (HP:0001257)**; **Pyramidal signs** | Moderate evidence; described as part of syndrome phenotype and later family expansion, but prevalence not well established (pqac-00000000, pqac-00000002) |
| Core phenotype: extrapyramidal | **Parkinsonism** can occur in the PPM-X/MECP2 male spectrum | HPO suggestion: **Parkinsonism (HP:0001300)** | Moderate evidence; likely represents part of the broader male MECP2 phenotypic spectrum rather than universal PPM-X finding (pqac-00000002, pqac-00000010) |
| Core phenotype: endocrine/reproductive | **Macroorchidism** is part of the defining triad/name | HPO suggestion: **Macroorchidism (HP:0000053)** | Strong as syndrome-defining terminology, but frequency and age-dependence in all carriers are not well quantified (pqac-00000000, pqac-00000002) |
| Additional neurologic/behavioral features | Speech delay, social withdrawal, anxiety, learning disability, cognitive slowing, microcephaly, rigidity and other variable male MECP2 features may occur across the spectrum | HPO suggestions: **Delayed speech and language development**, **Anxiety**, **Microcephaly**, **Rigidity** | Mostly extrapolated from broader male MECP2 case literature; not all are validated as canonical PPM-X features (pqac-00000002, pqac-00000008, pqac-00000009) |
| Molecular mechanism | Current understanding places MeCP2 in **methylated-DNA binding and transcriptional regulation**, especially via interaction with the **NCoR/SMRT corepressor complex**; MeCP2 dosage sensitivity is central | GO suggestions: **DNA-binding transcriptional regulation**; **chromatin organization** | Mechanistically strong for MECP2 biology overall, but not directly proven as the complete causal chain for PPM-X p.A140V specifically; use as informed extrapolation (pqac-00000002, pqac-00000005, pqac-00000009) |
| Cell type / tissue emphasis | Disease biology is expected to be primarily **neuronal/CNS**, with highest MeCP2 abundance in neurons | CL suggestion: **neuron**; UBERON suggestion: **brain** | Strong for MECP2 disorders generally; PPM-X-specific tissue studies are lacking (pqac-00000002, pqac-00000009) |
| Diagnosis | Diagnosis is best established by **molecular testing of MECP2** in males/families with X-linked intellectual disability plus psychiatric and neurologic features; exome/genome sequencing can help detect atypical MECP2 presentations | Gene testing target: **MECP2**; MONDO:0010235 | Strong conceptual support; no dedicated PPM-X diagnostic guideline located. Modern sequencing is favored because male MECP2 disorders can be overlooked or mistaken for other neuropsychiatric disease (pqac-00000003, pqac-00000004, pqac-00000008) |
| Differential diagnosis / classification caveat | PPM-X should be distinguished from **classic Rett syndrome**, **MECP2 duplication syndrome**, and other male MECP2-related neurodevelopmental disorders | Related entities: RTT, MECP2 duplication syndrome | Important caveat: broader MECP2 spectrum is heterogeneous, and features in males can differ substantially from classic RTT in females (pqac-00000002, pqac-00000008, pqac-00000009) |
| Treatment status | **No PPM-X-specific disease-modifying therapy** was identified; management appears **supportive and symptom-directed** (psychiatric, neurologic, developmental, rehabilitative, endocrine surveillance as indicated) | NCIT suggestions: supportive care / psychiatric management / rehabilitation | Evidence gap: no syndrome-specific interventional trials found. Care recommendations are inferred from rare-disease neuropsychiatric management rather than validated PPM-X protocols (pqac-00000003, pqac-00000004) |
| MECP2/Rett therapeutics relevance | Gene therapy and pathway-based Rett treatments exist in development for MECP2 disorders, but **should not be considered validated for PPM-X** | Caveat annotation: **extrapolated MECP2 evidence** | Critical distinction: Rett/MECP2-wide therapeutic data are not syndrome-specific and may not translate directly to p.A140V PPM-X because dosage and phenotype differ (pqac-00000007, pqac-00000008, pqac-00000009) |
| Epidemiology | PPM-X is **ultra-rare**; no reliable prevalence or incidence estimate was identified | Epidemiology field: **unknown / not established** | Strong evidence of rarity, but no modern registry-based estimate; published knowledge is based mainly on a few families and case reports (pqac-00000003, pqac-00000004) |
| Natural history | Course appears **chronic lifelong** with childhood neurodevelopmental issues and later-emerging psychiatric/neurologic manifestations in some males | HPO onset suggestions: childhood onset; progressive/variable course | Moderate evidence; natural history data are sparse and mostly pedigree-based, without standardized longitudinal cohorts (pqac-00000002, pqac-00000010) |
| Model organism | A syndrome-relevant **Mecp2 A140V mouse model** has been reported, including electrophysiological abnormalities | Model: **Mecp2 A140V mutant mouse** | Useful for mechanism, but still a model-system approximation of human PPM-X; does not capture the full human psychiatric phenotype (pqac-00000000, pqac-00000010) |
| Knowledge-base evidence boundary | For curation, separate **direct PPM-X evidence** (few pedigrees, A140V-linked syndrome, male phenotype) from **broader MECP2/Rett evidence** (mechanisms, biomarkers, therapies) | Annotation suggestion: **direct human evidence** vs **extrapolated MECP2 evidence** | Essential caveat for accurate knowledge-base use: the latter is biologically informative but not disease-specific validation for PPM-X (pqac-00000000, pqac-00000002, pqac-00000009) |


*Table: This table condenses the most actionable knowledge-base facts for PPM-X syndrome, including identity, gene, variant, core phenotype domains, and evidence caveats. It is especially useful for distinguishing direct syndrome-specific evidence from broader MECP2/Rett extrapolations.*